Do you know the difference between genetic and genomic testing and how it can impact your decisions following active surveillance protocols vs. treatment?
On Saturday, March 25th at Noon EST ASPI is premiering a segment of the AS 101 series aimed at educating patients about the differences between genetic and genomic testing.
Yale researchers recently reported that although patients generally understood the purpose of genomic testing in identifying their risk status, many needed to understand the difference between genomic testing and genetic testing.
Each of the AS101 sessions features prostate cancer patient Larry White, and his well-informed wife, Nancy White, speaking with top experts with their questions about AS issues in an office visit setting.
In this program, the Whites discuss genetics and genomics from a patient point of view with Justin Lorentz, M.Sc, a certified genetic counselor and lead of Sunnybrook Health Science Centre’s Male Oncology Research and Education (MORE) Program, a registry for men with hereditary cancer. Lorentz is an instructor at the University of Toronto and a consultant to the Promise study, which offers free DNA testing to men with prostate cancer.
AS 101, like an introductory college course, was launched in 2022 to explain in short video chats the basics of active surveillance for the newly diagnosed, those in the “gray zone” with rising PSAs but no biopsy confirming the presence of low-risk cancer, and also patients who have been on AS for a while but are looking for a refresher course. The entire series to date of AS 101 is available at: https://aspatients.org/a-s-
Title: Free Webinar: active surveillance 101 – The Differences Between Genetic And Genomic Testing
When: March 25, 2023 12:00 PM Eastern Time (US and Canada)
Special thanks to ASPI (active surveillance Patients International) for hosting this great topic of discussion.
